Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

Benzinga · 4d ago
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $49 to $45.